atrial fibrillation - embolic protection - all type of patients clinical trials results meta-analysis

<h1> <a href="TM10-115-embolic protection-atrial fibrillation" > <strong>atrial fibrillation</strong> - embolic protection </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9824.htm"> PROTECT-AF, </a> <br> NCT00129545 </td> <td> closure of the left atrial appendage(LAA) using the Watchman device<br>  <i>versus</i> <br> long-term warfarin therapy </td> <td> patients with documented nonvalvular atrial fibrillation who could take long-term warfarin, but without any indication that would require warfarin </td> <td> follow-up 900 patients-year<br> n=463/244<br> Parallel groups<br> open <br> US, Europe </td> </tr> </table> <h2>References</h2> <p> <b>PLAATO, : </b> Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, Williams DO, Reisman MPercutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. <i>JACC Cardiovasc Interv 2009 Jul;2:594-600</i> [PMID 19628179] 10.1016/j.jcin.2009.05.005 </p>